The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo
Metrics: PDF 136 views | HTML 446 views | ?
Atif J. Khan1,2, Stephanie LaCava2,3, Monal Mehta2, Devora Schiff2, Aditya Thandoni2, Sachin Jhawar2, Shabbar Danish4, Bruce G. Haffty2 and Suzie Chen3
1 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
2 Department of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
3 Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA
4 Department of Surgery, Division of Neurosurgery, Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
|Atif J. Khan,||email:||email@example.com|
Keywords: glutamate; glioma; riluzole; radiation therapy
Received: December 29, 2018 Accepted: March 23, 2019 Published: April 19, 2019
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.